Efficacy of curcumin as adjuvant therapy to improve remission in myeloma patients

ISRCTN ISRCTN14131419
DOI https://doi.org/10.1186/ISRCTN14131419
Secondary identifying numbers 3000113510022
Submission date
31/10/2019
Registration date
08/11/2019
Last edited
30/12/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. The therapy varies from chemotherapy, autologous bone marrow transplant, to novel agents . Chemotherapy for myeloma with Melphalan and prednisone produces an objective response in 50–60% of patients.

Curcumin is a natural polyphenol compound derived from turmeric (Curcuma longa). A number of preclinical studies have demonstrated that curcumin has anticancer effects against a variety of tumors, myeloma, both in vitro and in vivo. The safety of curcumin has been approved by the Food and Drug Administration and World Health Organization; In addition, its safety is strongly supported by the fact that this agent has been used in traditional Indonesia, India and Chinese medicine
The primary outcome of this study was to prove the efficacy of curcumin in the improvement of the remission status in myeloma patient. The secondary outcome was to evaluate the effect of curcumin to various disease activity, including NF-κB, IL-6, VEGF, TNF-α, CRP, and LDH.

Who can participate?
Multiple myeloma patients aged over 18 years who are ineligible for transplant

What does the study involve?
Patients will be randomly allocated to receive chemotherapy alone or chemotherapy plus curcumin for four 28 day cycles.

What are the possible benefits and risks of participating?
If the administration of curcumin can improve remission in the sample population, it certainly can be proposed as a useful complementary therapy

Where is the study run from?
Dr Kariadi General Hospital, Indonesia

When is the study starting and how long is it expected to run for?
February 2016 to February 2017

Who is funding the study?
LPDP (Lembaga Pengelola Dana Pendidikan), Indonesia

Who is the main contact?
Dr Damai Santosa
santosaivha@fk.undip.ac.id

Contact information

Dr Damai Santosa
Scientific

Jl. Dr. Sutomo no 16
Semarang
3374010
Indonesia

ORCiD logoORCID ID 0000-0002-6093-5049
Phone +6281325062592
Email santosaivha@fk.undip.ac.id

Study information

Study designInterventional randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet See additional files (in Indonesian)
Scientific titleThe effect of curcumin on remission status and survival on myeloma patients treated with melphalan prednisone: a pilot randomized clinical trial
Study hypothesis1. The addition of curcumin to treatment will increase overall remission in myeloma patients treated with melphalan prednisone
2. The addition of curcumin to treatment will decrease measures of NF-κB, IL-6, VEGF, TNF-α, CRP, and LDH in myeloma patients treated with melphalan prednisone
Ethics approval(s)Approved 17/02/2016, Komisi Etik Penelitian Kesehatan (Jl. Dr. Soetomo No18, Semarang City, Central Java Province, Indonesia, 50244; +62243818550), ref: 16/EC/FK-RSDK/I/2016
ConditionMultiple myeloma
InterventionPatients were allocated randomly in two parallel study groups using a sealed envelope method. The treatment group (17 patients) was treated with MP regimen (melphalan 4mg/m², prednisone 40mg/m², for 7 days) and curcumin 8 grams/daily for 28 days. The control group (16 patients) was treated with MP regimen and placebo. All of the patients were evaluated every 28 days for a total of 4 cycles treatment.

Each patient was followed up every 28 days, for 4 cycles. A checklist was used for data collection and filled in each visit separately. The contents of checklist were the patients' profiles (age, sex, education level), and laboratory data, including full blood count (FBC), urea, creatinine, NF-kB, IL-6, CRP, LDH, VEGF, and patient group (treatment or control). The physical exam of the patients was performed by a physician every visit (single blindness). Remission and TNF-a was evaluated after the end of study
Intervention typeSupplement
Primary outcome measureOverall remission at the end of the study period
Secondary outcome measuresLevels of NF-kB, TNF-a, VEGF, IL-6, CRP, LDH measured using blood test every 28 days throughout the study period
Overall study start date29/09/2015
Overall study end date30/06/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants20 participants, 10 in each group
Total final enrolment33
Participant inclusion criteria1. New multiple myeloma patients
2. Aged over 18 years old
3. Ineligible for transplant
Participant exclusion criteria1. Sepsis
2. Severe infection
3. Pregnancy
4. Patients with severe disease (such as acute hepatitis, chronic hepatitis, cirrhosis)
5. Elevation of aspartate aminotransferase (AST) >3 times upper limit normal (ULN)
6. Participated in another study
7. Poor performance status
Recruitment start date01/02/2016
Recruitment end date01/05/2017

Locations

Countries of recruitment

  • Indonesia

Study participating centre

dr. Kariadi General Hospital
Jl. Dr. Sutomo no 16
Semarang
3374010
Indonesia

Sponsor information

LPDP (Lembaga Pengelola Dana Pendidikan)
Government

Ministry of Finance of Republic of Indonesia
dr. Wahidin Raya Street No1
Jakarta
10710
Indonesia

Phone +6221-3500842
Email tesisdisertasi.lpdp@kemenkeu.go.id
Website http://www.lpdp.kemenkeu.go.id/program/pengelolaan-dana/#
ROR logo "ROR" https://ror.org/04wvvj212

Funders

Funder type

Government

Lembaga Pengelola Dana Pendidikan (LPDP)

No information available

Results and Publications

Intention to publish date03/03/2018
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThesis defence in Faculty of Medicine, Diponegoro University, March 2018
IPD sharing planThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. please contact Ms Haidi/Kiki, email address; hemasemarang@gmail.com, type of data=excel, the data will become available for 10 years, the access criteria data will be shared including with hematologist that interesting in myeloma research, the types of analyses dependent on their study purpose, and the mechanism; please send email to us with the study protocol and we will discuss to our ethical committee

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 01/04/2022 30/12/2022 Yes No

Editorial Notes

30/12/2022: Publication reference and total final enrolment added.
11/11/2019: Internal review.
08/11/2019: Trial’s existence confirmed by Komisi Etik Penelitian Kesehatan